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The cellular form of the prion protein (PrPC) is a highly con-
served glycoproteinmostly expressed in the central and periph-
eral nervous systems by different cell types in mammals. A mis-
folded, pathogenic isoform, denoted as prion, is related to a class
of neurodegenerative diseases known as transmissible spongi-
formencephalopathy. PrPC functionhasnot beenunequivocally
clarified, and it is rather defined as a pleiotropic protein likely
acting as a dynamic cell surface scaffolding protein for the
assembly of different signaling modules. Among the variety
of PrPC protein interactors, the neuronal cell adhesion mol-
ecule (NCAM) has been studied in vivo, but the structural
basis of this functional interaction is still a matter of debate.
Here we focused on the structural determinants responsible
for human PrPC (HuPrP) and NCAM interaction using stim-
ulated emission depletion (STED) nanoscopy, SPR, and NMR
spectroscopy approaches. PrPC co-localizes with NCAM in
mouse hippocampal neurons, and this interaction is mainly
mediated by the intrinsically disordered PrPC N-terminal
tail, which binds with high affinity to the NCAM fibronectin
type-3 domain. NMR structural investigations revealed sur-
face-interacting epitopes governing the interaction between
HuPrP N terminus and the second module of the NCAM
fibronectin type-3 domain. Our data provided molecular
details about the interaction between HuPrP and the NCAM
fibronectin domain, and revealed a new role of PrPC N termi-
nus as a dynamic and functional element responsible for pro-
tein-protein interaction.
Amisfolded form of the host-encoded cellular prion protein
(PrPC)3 is the causative agent for a class of human and animal
neurodegenerative diseases denoted as transmissible spongi-
form encephalopathies. PrPC is a sialoglycoprotein, tethered to
the outer leaflet of the plasma membrane by a glycosylphos-
phatidylinositol (GPI) anchor. Soluble, natively -helix-folded
monomers of PrPCmay adopt an aggregated protease-resistant
conformation known as PrPSc (1). The mature human PrPC
(HuPrP) is composed of 209 residues including a largely
unstructured N-terminal part and a globular -helix-rich
C-terminal domain (2). Conversely, PrPSc is -sheet-enriched,
partially protease-resistant, insoluble, and multimeric (3). The
insoluble nature of PrPSc and its propensity to aggregate have
hampered the use of high-resolution techniques, and therefore
different PrPSc models currently exist (4).
Despite the fact that PrPC is highly conserved among differ-
ent species, its physiological function has not been fully clar-
ified. Defining PrPC function remains one of the main chal-
lenges in prion biology, and it is also an absolute requirement
for understanding prion diseases. It is now being accepted
that PrPC is a pivotal molecule with diverse roles in brain
development and in neural plasticity in the adult (5–8). Pro-
posed PrPC functions range from neuronal growth and dif-
ferentiation (9), synaptic plasticity (10, 11), cell signaling (12,
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13), NMDA receptor regulation (14, 15), and brain metal
homeostasis (16). Putative functions are based on PrPC-in-
teracting molecules present on the cell surface, such as the
37-kDa/67-kDa laminin receptor, the stress-inducible pro-
tein 1, and vitronectin (17–19). Among the different PrPC
protein interactors, the neuronal cell adhesion molecule
(NCAM) has been extensively characterized in vitro, in cell-
based assays, and in vivo (13, 20–23).
NCAM belongs to Ig superfamily cell adhesion molecules
(CAMs), and it is present on the cell surface of neurons, astro-
cytes, and oligodendrocytes, where it mediates homophilic and
heterophilic cell adhesion (24). NCAM is involved in neuronal
migration, axon growth, and guidance, as well as in synaptic
plasticity associated with learning and memory (25). Alterna-
tive splicing of theNCAM1 gene results in isoforms of three size
classes that differ in their membrane attachment and cytosolic
regions: NCAM-180, NCAM-140 (with intracellular domains
consisting of 386 and 120 amino acids, respectively), and
NCAM-120 (lacking the intracellular domain and linked to the
membrane by a GPI anchor). NCAM isoforms share an extra-
cellular domain consisting of five Igs and two fibronectin type-3
(FNIII1,2) domains. Variable use of alternative exons in the
extracellular domain results in small insertions into Ig4 or
between the FNIII1,2 domains. NCAM function is further reg-
ulated by an unusual posttranslational modification consisting
of the addition of polysialic acid to Ig5 (26, 27). Although a
complete picture has yet to emerge, it appears that NCAM
physiological function is mediated bymultiplemodes of homo-
philic interaction through the NCAM Ig domains (28). Addi-
tionally, NCAM is also engaged in heterophilic interactions, i.e.
NCAM can bind other protein partners modulating different
functions. Different groups have investigated the structural and
molecular basis governing the interaction between the NCAM
FNIII1,2 domain and the fibroblast growth factor receptor 1
(FGFR1) (29, 30).
Besides the interaction with FGFR1, NCAM can bind PrPC
and engages different cellular responses. PrPC-NCAM binding
induces NCAM redistribution in lipid rafts, leading to FYN
tyrosine kinase activation and neurite outgrowth (13). ELISA
experiments using an NCAM-derived peptide library against
the recombinant full-lengthmouse prion protein (MoPrP) have
shown that the FNIII1,2 domain shares highest affinity for
MoPrP (21). As revealed by in situ cross-linking ofMoPrP dele-
tion mutants expressed in cell models, the PrPC-binding site
seems to be formed by the N terminus and a segment compris-
ing -helix 1 (21). However, PrPC-NCAM interacting surfaces
have not been described at the structural and biophysical levels
yet. Recently, it has been observed that PrPC controls polysia-
lylation of NCAMduring cellular morphogenesis (23). Current
evidence strengthens the hypothesis that the FNIII1,2 domain
plays a role for NCAM-mediated heterophilic interaction;
therefore this domain may represent a useful model for struc-
tural studies aiming at understanding the molecular determi-
nants of PrPC-NCAM interaction.
Here we have performed cell biology, biophysical, and struc-
tural investigations on the interaction between the FNIII1,2
domain and HuPrP. Despite the inherent structural disorder of
the PrPCN-terminal domain, which canmediate its interaction
with bothmetals and cellular polyanions (e.g. sulfate proteogly-
cans) (31), binding with physiological protein partners has not
been proved yet. HuPrP segments that are able to interact with
the FNIII1,2 domainwere identified by SPR experiments. NMR
chemical shift perturbation experiments allowed us to identify
binding sites on the FNIII1,2 domain involved in the interaction
with the HuPrP. The module 2 (FNIII2) of the fibronectin
type-3 domain and peptides covering different parts of the
HuPrP were employed as a model system. Additionally, we
examined the effect of a pathological amino acid substitution,
P102L, the prototypical mutation linked to a genetic form of
human prion disease denoted as Gerstmann-Straussler-Schei-
nker disease (GSS), on binding to FNIII2. Interestingly, this
mutation also unveiled a new hidden binding site correspond-
ing to the non-octarepeat copper-binding site (32). These
results may provide a structural understanding of the interac-
tion of NCAMwith PrPC and where the binding site is located.
Besides, the novel insight of the effect of HuPrP bearing the
pathogenic point mutation P102L on its interaction with the
FNIII2 domain is introduced here.
Results
NCAM Co-localizes with PrPC—Functional interactions of
PrPCwith its binding partner(s) have been suggested previously
(13): cis and trans interactions between NCAM and PrPC pro-
mote neurite outgrowth, and the disruption of these interac-
tions indicates that PrPC is involved in nervous system devel-
opment cooperating with NCAM as a signaling receptor.
In this study, we used stimulated emission depletion (STED)
nanoscopy to confirm the association between PrPC and
NCAM in mouse hippocampal culture. We determined simul-
taneously the cellular distribution of PrPC, NCAM, and actin
(Fig. 1A). PrPC and NCAM share very similar distributions
along the neurite and in hippocampal growth cones (GC). The
staining for PrPC andNCAMwas preferentially localized in the
central domain and transition zone of the GC membrane (Fig.
1A, arrows). By using STED nanoscopy, we were able to detect
very low co-localization between PrPC and NCAM, whereas
treatment with 1 M nerve growth factor (NGF) results in
increased co-localization (Fig. 1B). The observed higher associ-
ation between PrPC and NCAM in treated cultures suggested
that these proteins might functionally cooperate to transduce
signals into the cell interior, which in turn trigger the neurite
growth.
FNIII1,2 Domain Binds to HuPrP N-terminal Domain with
High Affinity—SPR experiments were used to analyze the bind-
ing of the FNIII1,2 domain to different HuPrP and MoPrP
constructs, including full-length HuPrP and MoPrP (i.e. from
residues 23 to 231 and 23 to 230, respectively), the HuPrP
N-terminal domain (residues 23–144), and the truncated
C-terminal HuPrP and MoPrP (residues 90–231 and 89–230,
respectively). We observed strong interaction between the
FNIII1,2 domain and the HuPrP N-terminal domain with Kd of
5.4 nM. Also the full-length HuPrP binds to the FNIII1,2
domain (Kd of 337 nM), whereas for the truncated HuPrP, we
were not able to report any interaction. The full-length
MoPrP displayed a weak affinity for the FNIII1,2 domain (Kd
3.8 M), whereas the truncated MoPrP behaved almost iden-
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tically to the truncated HuPrP, displaying no interaction
with the FNIII1,2 domain (Table 1 and Fig. 2). Additionally,
we confirmed that a short NCAM peptide, named BCL, cor-
responding to the sequence of residues 620–635 in the
FNIII1,2 domain, is able to interact with HuPrP using ELISA
(Fig. 3). Peptide BCL also binds to MoPrP (21), and it is
considered an NCAM mimetic peptide employed as NCAM
surrogate in pharmacological experiments (34). These data
add more insights about the HuPrP regions involved in the
FIGURE 1. PrP-NCAM interaction in vitro. A, STED images of GC stained for PrP, NCAM, and actin, and merge of the PrP and NCAM in control condition.
Scale bar, 500 nm. A1 and A2, high-resolution images of areas indicated in A. Scale bar, 250 nm. B, as in A, except that neurons were incubated with 1 M
NGF (2 h).
TABLE 1
Dissociationconstants for the interactionbetweenFNIII (immobilized)
and different HuPrP andMoPrP constructs
NA, not applicable.
Protein Kd Kon Koff
nM 1/ms 1/s
HuPrP(23–231) 337 2.00E05 0.0674
HuPrP(90–231) NA NA NA
HuPrP(23–144) 5.4 1.42E06 7.66E-03
MoPrP(23–230) 3800 2.58E04 0.0983
MoPrP(89–230) NA NA NA
PrPC N Terminus-mediated Cross-talk with NCAM
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interaction with the FNIII1,2 domain, showing that this
binding is largely mediated by the unstructured N-terminal
HuPrP domain.
FNIII2DomainWasUsed forNMRCharacterization of Bind-
ing between HuPrP and NCAM—NMR spectroscopy is an
excellent tool to evaluate and characterize the binding proper-
ties of HuPrP andNCAM in solution at atomic level. Unambig-
uous assignment of HuPrP(23–144) residues was not possible
because of high signal overlap in the 15N HSQC spectrum,
which was due to the high percentage of glycine residues, oct-
arepeats, and intrinsically disordered properties of the unstruc-
tured N terminus (supplemental Fig. S1A). Thus, we focused of
the HuPrP interaction partner instead. 15N,13C-labeled FNIII1
and FNIII2 domains of NCAMwere produced to find a suitable
candidate for the evaluation of HuPrP-NCAM binding proper-
ties. The 15N HSQC spectra of the FNIII1,2 (supplemental Fig.
S1, B–D), FNIII1, and FNIII2 (Fig. 4) domains were recorded.
The FNIII1,2 and FNIII1 domains did not exhibit suitableNMR
properties for further analysis, whereas for the FNIII2 segment
(with a molecular mass of 11.8 kDa), a complete NMR analysis
has been carried out.
The 15N HSQC spectrum of the FNIII2 domain demon-
strated good dispersion of cross-peaks, indicating the potential
for detailed structure characterization (Fig. 4). The sequence-
specific assignment was performed with the use of standard
triple resonance NMR experiments to obtain the structure at
atomic resolution. The structure of the FNIII2 domain was cal-
culated using 778 intra-residual and sequential restraints, 108
medium-range and 772 long-range distance restraints, and 136
backbone torsion angle restraints (Table 2). The calculated
FIGURE 2. SPR analysis of the FNIII-HuPrP or MoPrP interactions. Shown are raw sensorgrams obtained on a Biacore 2000 instrument. Selected curves are
labeled with the respective analyte concentration. A–C, the binding of full-length HuPrP (A), HuPrP N terminus (B), and full-length MoPrP (C) to immobilized
FNIII. RU, response units.
PrPC N Terminus-mediated Cross-talk with NCAM
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three-dimensional model showed that the FNIII2 domain con-
sists of six antiparallel -strands, marked A–F on Fig. 5. They
are arranged into two right-handed -sheets that form a
-sandwich. The first -sheet is composed of strands A and
D (residues Ser616–Asn620 and His657–Lys661, respectively),
whereas the second -sheet is composed of strands B, C, E, and
F (residues Ile631–Ala640, Ile649–Pro652, Tyr669–Asn677, and
Ala685–Phe687, respectively).
NMR approaches of biomolecular complexes are usually
challenging because of the increase of molecular weight due to
the interaction between partners. Clearly, a large number of
similar cross-peaks will be observed and will result in the over-
lapped spectra and increased linewidths associated with the
slower tumbling of a high molecular mass complex. Note that
increased line widths of cross-peaks are also expected in the
spectrum.Moreover, sometimes, macromolecular interactions
lead to several line broadenings through the enhanced relax-
ation that resulted in decrease and even loss of cross-peaks of
interest (35, 36). Multidimensional heteronuclear NMR
experiments were used to evaluate binding properties
between the FNIII2 domain andN-terminal HuPrP(23–144).
Interestingly, no amide chemical shift changes ((H,N))
were observed in the 15N HSQC spectrum of the FNIII2
FIGURE 3. ELISA showing the interaction between BCL peptide (620-
NLIKQDDGGSPIRHYL-635) and full-lengthHuPrP.AU, arbitrary units. Error
bars indicate S.E.
FIGURE 4. 15NHSQC spectrumof FNIII2 domainwith assignment of back-
bone amino acid residues indicated.
TABLE 2
NMR restraints and structural statistics for the ensemble of 20 lowest-
energy structures of the FNIII2 domain
NOE upper distance limitsa
Total 1658
Intra-residue (i j 0) 337
Sequential (i j 1) 441
Medium-range (1 i j 5) 108
Long-range (i j 5) 772
Torsion angle restraints
Backbone (/) 136
RMSD to the mean coordinates (Å)
Ordered backbone atoms (595–691) 0.28 0.09
Ordered heavy atoms (595–691) 0.78 0.08
Ramachandran plot (595–691)b
Residues in most favored regions (%) 88.8
Residues in additional allowed regions (%) 11.2
Structure Z-scoresb
1st generation packing quality 0.419 0.568
2nd generation packing quality 7.386 2.149
Ramachandran plot appearance 3.376 0.339
-1/-2 rotamer normality 6.283 0.259
Backbone conformation 0.441 0.137
RMS Z-scoresb
Bond lengths 1.201 0.004
Bond angles 0.581 0.008
	 angle restraints 0.758 0.030
Side chain planarity 0.437 0.029
Improper dihedral distribution 0.779 0.016
Inside/Outside distribution 1.029 0.011
aNone of the 20 structures exhibit distance violations over 0.2 Å and torsion angle
violation over 5°.
b Ensemble of structures was analyzed by the PROCHECK-NMR andWhatIF pro-
grams incorporated in the CING structure evaluation package (54) and PSVS
(55).
FIGURE 5.Ensembleof 20 lowest-energy structures of FNIII2 domain (res-
idues 595–691). The -strands are highlighted using letter codes (Protein
Data Bank ID 5LKN).
PrPC N Terminus-mediated Cross-talk with NCAM
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domain during a titration experiment with HuPrP(23–144)
at pH 7.0 (Fig. 6A). However, the FNIII2 sample became
blurred upon rising concentration of HuPrP(23–144), pre-
sumably because of interactions between partners that also
led to insoluble aggregates. Analysis of cross-peak linewidths
and absence of chemical shift changes in the 15N HSQC
spectra of FNIII2 resulted in the conclusion that cross-peaks
correspond to the unbound state of the labeled FNIII2
domain. Additionally, we tried to thermally disrupt multim-
eric complex at 45 °C to gain the monomeric form of the
complex. Although the sample cleared up, indicating that
the multimers fell apart, the 15N HSQC spectrum did not
improve after thermal treatment. Certainly, even smaller
multimeric complexes were still too big to be observed by
NMR. Titration was replicated at pH 6. The pH was
decreased to achieve favorable conditions where the com-
plex would not precipitate and would be stable often enough
that we could observe chemical shift changes of the recorded
the 15N HSQC spectra of FNIII2 upon rising concentration
of HuPrP peptides. (H,N) were observed in the 15N HSQC
spectra of the FNIII2 domain at a ratio 1:0.5 for residues
Arg599, Glu600, Gly614, Arg639, Ser642, Asp656, Ser664, Tyr669,
Tyr672, Gln678, Lys683, His686, and Val688 (Fig. 7A). However,
the cross-peaks in the 15N HSQC spectra of the FNIII2
domain disappeared at the ratio 1:2, most likely because of
the stacking and forming of aggregates, similarly as observed
at higher pH.
Interactions between FNIII2 Domain and Peptides Originate
fromHuPrPNTerminus—To determine the epitope onHuPrP,
itsN-terminal part was divided into smaller fragments. Gradual
titrations of the FNIII2 domain with individual peptides
HuPrP(23–89), HuPrP(23–50), HuPrP(60–68), HuPrP(93–
114), and HuPrP(93–114, P102L) were performed to the final
ratio between the protein and peptides of 1:2. Upon titrations
with HuPrP(23–89), HuPrP(93–114), and HuPrP(93–114,
P102L), the (H,N) values were observed in the 15N HSQC
spectra of the FNIII2 domain (Figs. 6C and 7, B and C). In
contrast, we did not identify any (H,N) values of the FNIII2
domain with peptide HuPrP(60–68) and negligible ones with
peptide HuPrP(23–50) (Fig. 6, B and D, respectively). For all
titration studies, the(H,N) values of the FNIII2 domain were
calculated using Equation 1 (see “Experimental Procedures”).
Titrations with peptides HuPrP(23–144), HuPrP(23–89), and
HuPrP(93–114, P102L) resulted in the biggest (H,N) values
of the FNIII2 domain. Interestingly, the biggest(H,N) values
were observed for residues Tyr669, Val673, His686, Phe687, and
Val688 of the FNIII2 domain. Other cross-peaks of the FNIII2
domain exhibit negligible chemical shift changes. Detailed
analysis of the(H,N) values for the FNIII2 domain presented
in Fig. 8 led us to conclude that residues Tyr669, Val673, His686,
FIGURE 6. 15N HSQC spectra of FNIII2 domain overlaid with 15N HSQC spectra of FNIII2 domain titrated with peptides originating from HuPrP. A,
HuPrP(23–144).B, HuPrP(60–68).C, HuPrP(93–114), HuPrP(93–114).D, HuPrP(23–50). TheHuPrPpeptide to FNIII2 equivalents andpHvalues are indicatedwith
the corresponding spectra.
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Phe687, and Val688 of the FNIII2 domain are involved in the
interaction with HuPrP.
Interactions between FNIII2 Domain and HuPrP(93–114,
P102L)—Because peptideHuPrP(93–114, P102L) exhibited the
strongest interactions with the FNIII2 domain, we examined
the effects of the interaction on the peptide as well. The 15N
HSQC, NOESY, TOCSY, and 13C HSQC spectra of aliphatic
and aromatic regions were used for chemical shift assignment
of unlabeled peptide. 13C-15N 	1-filtered 2D NOESY/TOCSY
and 13C-15N 	1-filtered 3D 15N HSQC-NOESY were used to
determine inter- and intramolecular contacts in complex.
Upon binding, no intermolecular contacts were observed in
13C-15N 	1-filtered 2D NOESY. The largest intramolecular
chemical shift changes were observed for cross-peaks in 13C-
15N 	1-filtered 2D TOCSY of amino acids Trp99, His111,
Met112, and Ala113 of HuPrP(93–114, P102L).
Experimental data therefore indicate that amino acid resi-
dues Tyr669, Val673, His686, Phe687, and Val688 of the FNIII2
domain and Trp99, His111, Met112, and Ala113 of HuPrP(93–
114, P102L) aremost probably involved in the interaction of the
NCAMdomain andWTHuPrP. These data were used as dock-
ing restraints for HADDOCK calculation (37, 38). 131 lowest-
energy structures were grouped into 13 clusters according to
RMSD values. The numbers of structures in the 10 best clusters
varied from 4 to 34 with their HADDOCK scores ranging from
71.8 to 53.5. The clusters could be split into two groups of sim-
ilar size. The first model describes the interactions between
Trp99 on HuPrP(93–114, P102L) and the FNIII2 domain,
whereas the second one describes the interactions of His111–
Ala113 with HuPrP(93–114, P102L) and the FNIII2 domain
(Fig. 9).
Discussion
Among the variety of PrPC protein interactors (37), PrPC
associates with NCAM in vivo. Bothmolecules have been inde-
pendently implicated in nervous system development and may
play a role in neural stem cells (9, 38, 40). PrPC recruits to and
stabilizes the transmembrane NCAM isoforms (NCAM-180
and NCAM-140) in lipid-rich microdomains. This activates
FYN kinase and promotes neurite outgrowth by cis and trans
interactions (13, 41). The interaction of these two molecules
and their relation to specific signaling pathways during neuro-
development merits further investigation at the structural and
molecular level, not the least because the physiological role of
PrPC may provide novel insights into the neuropathology of
prion diseases.
Along this line, the structural basis of the cross-talk between
PrPC and NCAM has not been previously investigated. In this
study, we have performed a structural investigation on the
interaction between the recombinant FNIII2 domain ofNCAM
and different peptides originating from N-terminal human
PrPC using different experimental approaches.
The in vitro experiments designed to confirm the co-lo-
calization of PrPC and NCAM in hippocampal neuron cul-
tures led us toward a better understanding of this interac-
tion. We have identified the HuPrP and MoPrP segments
able to interact with the FNIII1,2 domain by means of SPR
experiments. These experiments have unveiled that the
N-terminal HuPrP domain mediates the FNIII1,2 domain
binding with high affinity.
X-ray approaches have been previously applied to better
understand the structural properties of the FNIII1,2 domain
(42). Interestingly, the comparison between the FNIII2 NMR
structure and the corresponding x-ray structure revealed local
structural differences in the length of -strands. In particular,
although the NMR structure features two short -strands (A
and D) on one protein side and four -strands (B, C, E, and F)
on the other, the x-ray structure is characterized by seven
FIGURE 7.Overlays of 15N HSQC spectra of FNIII2 domain in the presence
of peptides originating from HuPrP at pH 6. A, HuPrP(23–144). B,
HuPrP(23–89). C, HuPrP(93–114, P102L). The HuPrP peptide to FNIII2 equiva-
lents are indicated with the corresponding spectra.
PrPC N Terminus-mediated Cross-talk with NCAM
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-strands (supplemental Fig. S2). Structural discrepancies
between diffraction and NMR data are to be expected con-
sidering the differences of the two methods in terms of spa-
tial distribution of the molecules in the sample and time
scales accessible to each method. Notably, solution NMR
data represent an average over semi-randomly oriented mol-
FIGURE 8. Chemical shift changes (H,N) for FNIII2 domain upon interaction with peptides originating from HuPrP at pH 6. 0. A, HuPrP(23–144)
peptide at ratio 1:0.5. B, HuPrP(93–114, P102L) at ratio 1:2.C, HuPrP(23–89) at ratio 1:2. The(H,N) valueswere calculated using Equation 1 (see “Experimental
Procedures”).
FIGURE 9. Low-resolutionmodel of complex between FNIII2 domain and HuPrP(93–114, P102L). A, ensemble of 40 models of the complex between
the FNIII2 domain (pink) and HuPrP(93–114, P102L) (green or orange depending on whether it interacts with His111–Ala113 or Trp99, respectively)
clustered by the HADDOCK program (4 models from each of 10 clusters). B, enlarged binding region of the best HADDOCK model of the FNIII2
domain-HuPrP(93–114, P102L) complex. Amino acids involved in the interaction are presented with balls and sticks (FNIII2 domain in blue, HuPrP(93–
114, P102L) in green).
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ecules in solution detected in a nanosecond-to-second time
regime, whereas diffraction data represent an average over
molecules arranged in a periodic crystal lattice acquired in a
seconds time scale.
We have performed NMR experiments designed to identify
the binding sites on the FNIII2 domain and HuPrP N terminus
responsible for the interaction. The implications of our findings
are important in prion biology as we provide the first structural
evidence that NCAMmediates the interaction with the N-ter-
minal domain of HuPrP through its FNIII1,2 domain. We pro-
pose a model where this largely unstructured segment acts as a
dynamic element able to recruitNCAMmolecules and tomedi-
ate physiological processes. We found that the WT HuPrP
mediates binding with the FNIII2 domain via its N-terminal
segment (residues 23–144). Interestingly, the N terminus con-
tains a glycosaminoglycan (GAG)-binding motif. The binding
ofGAG is important in prion diseases. This idea is supported by
evidence that mutant recombinant PrP binds more GAG,
which promotes the aggregation of mutant recombinant PrP
more efficiently than HuPrP wild type (43). Thus, our present
data corroborate the idea that besides binding metal ions and
GAG, the N-terminal domain also mediates cis interactions
with the NCAM fibronectin domain.
As opposed to WT HuPrP, the P102L mutant seems to pos-
sess an extra binding site localized in the segment 93–114, also
denoted as the non-octarepeat copper-binding site (32, 44).
Peptides HuPrP(93–114) and HuPrP(93–114, P102L) have the
same position in HuPrP N terminus except for the proline-to-
leucine substitution at residue 102. Comparison of the(H,N)
values for the FNIII2 domain after titration with both
HuPrP(93–114) andHuPrP(93–114, P102L) led to a conclusion
that the interaction of the latter with the FNIII2 domain is
stronger. Thus, we argue that P102Lmutation may affect bind-
ing with the FNIII2 domain, presumably leading to a stronger
interaction with NCAM, which in turn may lead to abnormal
Src family kinase activation.
These findings about the interaction between HuPrP and
NCAMmayhave biological relevance on prion conversion.Dif-
ferent compounds, including antibodies or chemical drugs,
with high affinity for PrPC have been employed as candidates
for therapeutic approaches aimed at inhibiting prion replica-
tion. This approach postulates that any PrPC ligand acts as
molecular chaperone able to stabilize the protein folding, thus
limiting the conversion to PrPSc. NCAM does not play a direct
role during prion formation as observed in NCAM knock-out
mice showing the same incubation periodwhen comparedwith
wild-type mice infected by prions (21). It is plausible that any
interference with NCAM-mediated signaling in the diseased
brain may favor cell death and inhibit synaptic plasticity. The
interactions between PrPC and NCAM could therefore be
reduced by accumulation of PrPSc in the diseased nervous sys-
tem. Thus, it is conceivable that the association of NCAM to
PrPC favors functional signaling pathways through FYN, which
is also implicated in synaptic functions. Furthermore, PrPC-
NCAMcrosstalk is crucial for the coordinated regulation of cell
cycle progression and the differentiation of neuronal precur-
sors toward different neuronal phenotypes (40). We found that
this interaction is mediated by the PrPC N terminus, particu-
larly in the segment from residues 23 to 50. This includes four
positively charged residues (i.e.KKRPK) known to play a role in
the PrPC endocytic trafficking and in its localization to lipid
rafts (45, 46). Our study suggests that the interaction between
residues 23–50 and the NCAM fibronectin domain may deter-
mine the fate of PrPC in the cell surface raft domain. Here PrPC
participates in the complex molecular networks and signaling
mechanisms, both cell-intrinsic and cell-extrinsic, that influ-
ence cell fate and differentiation.
The mechanisms that recruit and assemble different trans-
membrane signaling molecules to distinct membrane sub-
domains have only started to emerge. In these environments,
signaling and scaffolding proteins can self-associate and form
dimeric or multimeric assemblies. Protein dimerization has
been reported as a commonmechanism to cluster downstream
signaling components and thereby enhance the signaling cas-
cade (47). According to a recent model, NCAM is present on
the cell surface as cis dimers, formed by the interactions
between the Ig1 and Ig2 domains (48, 49). The role of cis
dimerization in NCAM dimerization is debated, but it is a pre-
requisite forNCAMclustering on the cell surface, which in turn
results in cell-cell adhesion via trans interactions between
NCAM clusters.
We described a strong interaction between HuPrP N termi-
nus and FNIII1,2 and the formation of multimeric complexes
formed upon the addition of FNIII2 to HuPrP(23–144). This
may have important physiological implications as PrPCmay act
as a scaffolding protein able to facilitate the FNIII1,2-mediated
NCAM self-assembly and clustering in the lipid raft.
In conclusion, we provide structural evidence that NCAM
mediates a heterophilic interaction through FNIII1,2 and the
N-terminal domain of HuPrP. Importantly, we propose that this
largely unstructured segment acts as dynamic element able to
recruit NCAMmolecules and tomediate physiological processes.
Experimental Procedures
Cell Culture—P1-P2 FVBWTmicewere sacrificed by decap-
itation in accordance with the guidelines of the Italian Animal
Welfare Act.
Immunostaining—Cells were fixed in 4% paraformaldehyde
containing 0.15% picric acid in PBS, saturated with 0.1 M gly-
cine, permeabilized with 0.1% Triton X-100, saturated with
0.5% BSA (all from Sigma-Aldrich) in PBS, and then incubated
for 1 hwith primary antibodies followedby a 30-min incubation
with secondary antibodies conjugated with STAR580 or
STAR635P (Abberior, Go¨ttingen, Germany). All incubations
were performed at room temperature (20–22 °C).
STED Microscopy—Two-color STED microscopy was per-
formed at the NanoBiophotonics Department (Max Plank
Institute for Biophysical Chemistry, Go¨ttingen, Germany) (50)
equipped with 561- and 640-nm pulsed excitation lasers, a
pulsed 775-nmSTED laser, and a 100	 oil immersion objective
lens (NA 1.4).
Plasmid Construction—The FNIII1,2 and FNIII2 domains
were PCR-amplified from pCEP-Pu vector encoding for
FNIII1,2 (kindly provided by Dr. Federico Carafoli, Imperial
College London, London, UK) and inserted into a modified
pET11a vector (i.e. carrying a C-terminal uncleavable His tag)
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using a restriction-free cloning protocol. Our FNIII1,2 and
FNIII1 numbering schemes correspond to Carafoli et al. (42).
Protein Expression and Purification—A freshly transformed
overnight culture of Escherichia coli BL21 (DE3) cells (Strat-
agene) transformed with pET11a encoding for FNIII1,2 or
FNIII2 was added at 37 °C to 2 liters of minimal medium. For
isotope labeling, 4 g/liter [13C6]glucose and 1 g/liter [15N]am-
monium chloride were added. At 0.8 A600, expression was
induced with isopropyl--D-galactopyranoside to a final con-
centration of 0.25 mM. Cells were grown in a BIOSTAT B plus
2-liter vessel (Sartorius) andharvested 18h after inoculation. Bac-
terial paste was resuspended in 25 mM Tris-HCl, 0.8% Triton
X-100, 1 mM PMSF, pH 8, and lysed by a Panda homogenizer.
Crude extract was loaded onto a 5-ml HisTrap column (GE
Healthcare) equilibrated in PBS buffer, pH 7.45 (140mMNaCl, 10
mMNa2PO4, and 3 mM KCl), and then eluted with 500 mM imid-
azole inPBS.Theproteinwas thendialyzedagainstTBSbuffer, pH
7.45, using a Spectra/Por membrane (molecular weight, 10,000).
The HuPrP(23–231), HuPrP(90–231), and HuPrP(23–144)
were expressed, purified, and in vitro refolded according to our
previous protocols (32). Peptides HuPrP(23–89), HuPrP(23–
50), HuPrP(60–68), HuPrP(93–114), and HuPrP(93–114,
P102L) (Table 3) were purchased from Chematek SpA.
NCAM-PrP Affinities Were Determined Using Surface Plas-
mon Resonance—Binding kinetics were determined on Biacore
2000 (GE Healthcare). Ten g of NCAM was diluted in 10 mM
NaOAc, pH 5.2, and immobilized on a CM5 chip activated with
NHS and N-ethyl-N-(3-dimethylaminopropyl) carbodiimide
(EDC), using a flow rate of 5 l/min. A steady signal of about
400 response units was obtained after immobilization and
blocking with ethanol amine. All kinetic SPR analyses were run
at a flow rate of 30 l/min in PBS, 0.05% Tween 20, and 3 mM
EDTA at 25 °C. After each cycle, the surface was regenerated
with a 60-s pulse of 100 mM glycine, pH 1.5. Association rates
(Kon) and dissociation rates (Koff) were obtained using a 1:1
Langmuir binding model (Biacore evaluation software version
4.1). The equilibrium dissociation constant (Kd) was calculated
from the ratio Koff/Kon.
Confirming BCL-HuPrP Interaction with ELISA—BCL was
immobilized at 0.5Mand titratedwith full-lengthHuPrP (0–5
M). Antigen was detected using anti-PrPC SAF34 antibody
that recognizes an epitope corresponding to the octapeptide
repeat region (residues 60–91) (51).
NMR Spectroscopy—All NMR experiments used for struc-
ture determination were performed on 13C,15N isotopically
labeled FNIII2 domain on the Varian VNMRS 800-MHz NMR
spectrometer equipped with a triple 1H/13C/15N resonance
cryogenic probe head with inverse detection at 298 K. The
NMR sample contained 0.9 mM FNIII2 domain in 50 mM TBS
buffer, pH 7.45, and 150 mM NaCl. NMR experiments for HN
and HC detection were performed in 90%/10% H2O/D2O and
100% deuterated buffer, respectively. The sequence-specific
assignment of the backbone resonances for the FNIII2 domain
was obtained using standard double resonance 15N HSQC and
triple resonance NMR experiments HNCO, HN(CO)CA,
HNCA, HN(CO)CACB, andHNCACB. 1H and 13C resonances
of aliphatic and aromatic side chains were assigned using 13C
HSQC and HAHB(CO)NH, CC(CO)NH, (H)CCH-TOCSY,
and 13C-edited HSQC-NOESY experiments. NOE contacts
were determined in 3D 15N- and 13C-edited HSQC-NOESY
experiments toperformstructure calculation.The structuremod-
eling of the FNIII2 domain was performed using the program
CYANA 3.0 (52). Structure refinement using the explicit solvent
modelwasperformedby theYASARAprogram(53).Anensemble
of 20 lowest-energy structures of the FNIII2 domainwas validated
by the web server software ICing (54) and PSVS (55).
Titration of 13C,15N isotopically labeled FNIII2 domain with
unlabeled HuPrP(23–144) was performed in 25 mM HEPES
buffer, pH 7.00. Titrations of labeled FNIII2 domain were also
done with unlabeled HuPrP(23–50), HuPrP(23–89), HuPrP
(60–68), HuPrP(93–114), and HuPrP(93–114, P102L) pep-
tides at pH 6.00 (20 mMNaOAc buffer, 0.35 mM labeled FNIII2
domain per titration experiment). Titrations were followed by
analysis of the (H,N) of the FNIII2 domain in 15N HSQC
experiments. All recorded spectra were processed by the
NMRPipe (56) software and analyzed with the CARA (57) and
SPARKY (58) software.
Amide chemical shift changes were calculated for each non-
overlapped cross-peak in the 15NHSQCspectrumof the FNIII2
domain according to Equations 1 and 2

H,N 
 
H2  
0.154 	 N2 (Eq. 1)
H,N 
 H,N bound  H,N free (Eq. 2)
where H and N are defined as the difference in the 1H and
15N amide chemical shifts between the protein-peptide com-
plex and the free state of the FNIII2 domain (59).
Modeling the Complex between FNIII2 Domain and HuPrP
(93–114, P102L)—Modeling of the complex between the
FNIII2 domain and HuPrP(93–114, P102L) was made with the
HADDOCK software (33, 39).
TABLE 3
Amino acid sequences of peptides originating fromN-terminal HuPrP thatwere used for characterization of binding properties betweenHuPrP
and NCAM
Names of peptides Amino acidic sequences
HuPrP(23–144) KKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHG
GGWGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSD
HuPrP(23–89) KKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGW
HuPrP(23–50) KKRPKPGGWNTGGSRYPGQGSPGGNRYP
HuPrP(93–114) GGTHSQWNKPSKPKTNMKHMAG
HuPrP(93–114, P102L) GGTHSQWNKLSKPKTNMKHMAG
HuPrP(60–68) PHGGGWGQ
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